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Introduction
In 2002, a clinical trial designed to
evaluate optimal ventilation practice [1,2]
for patients with acute respiratory distress
syndrome (ARDS) sparked a major contro-
versy. Critics charged that management of
ARDS in the different arms of the study did
not adequately reflect usual medical care,
and alleged that it was essential for scientific
and ethical reasons to have a usual care
comparison arm in the study. The contro-
versy over trial design enmeshed the
National Institutes of Health (NIH), the
Office for Human Research Protections
(OHRP) and the critical care research
community. The trial was put on hold and
reviewed by two independent expert panels.
Experts pointed to the need for further
analysis of the scientific and ethical issues
involved in choosing trial designs when
there is no consensus on standard of care.
In November 2005, NIH and a number
of other federal agencies sponsored a
meeting (see Text S1) to discuss clinical
trial design challenges involving selection
of usual care comparison groups (Text S1).
The meeting was informed by a back-
ground paper (Text S1) outlining types of
challenges involved in selecting usual care
arms, prepared by a working group with
expertise in clinical trial design, ethics,
evidence-based medicine, statistics, and
science policy. We present here the
background framework and case studies
used in this paper (Text S1). We enumer-
ate five factors that make consensus on
these issues particularly difficult, and
recommend specific criteria for assessing
proposed study designs.
Terminology
Terms such as ‘‘standard of care,’’ ‘‘control
arm,’’ ‘‘usual care,’’ and ‘‘community care’’
have all been used to describe arms reflecting
conventional therapy. We use the term
‘‘usual care’’ to describe the care commonly
given by practitioners in a community to
avoid any legal or normative implications of
the term ‘‘standard of care.’’
Determining When a Usual Care
Arm Will be Needed
There may be scientific, ethical, and/
or practical reasons for having an arm in
a clinical trial that employs usual care.
If researchers hypothesize that a new
intervention is better than or at least
equivalent to current clinical practice,
then one trial arm needs to reflect usual
care. Ethically, the clinical care commu-
nity must be in a state of equipoise prior
to randomizing patients to different
interventions [3], although there is no
universal view on how to evaluate or
resolve disagreements on the existence of
equipoise in a particular scenario. If
clinicians or investigators believe that
usual care is effective, a usual care
comparison may increase trial accept-
ability. A usual care arm might improve
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Summary Points
N Challenges often arise when researchers propose clinical trials incorporating
usual care comparison groups.
N Disagreements may arise about current levels of evidence supporting usual care
or failures to use best known methods in clinical practice; about the need for
customized care, or about the difficulty in choosing best treatments when
available interventions have trade-offs.
N Clinical trial designs incorporating usual care arms must be based on scientific
validity, consideration of risks and benefits to patients, relevance to the clinical
care community, and feasibility.
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ticality of the study.
Challenges in Formulating
Comparison Groups
Representing Current Medical
Care
Five types of difficulties can arise in
defining a comparison group, and several
of these conditions often coexist: (1)
disputes about evidence; (2) low level of
utilization of best methods; (3) trade-offs
relating to physician and patient prefer-
ences for different treatments; (4) an
insufficient preexisting evidence base to
guide treatment selection; and (5) individ-
ually customized medical care for condi-
tions with no standard practice guidelines.
Underlying these issues are two funda-
mental tensions. First, there is tension
between the need for control over exper-
imental conditions and the need for trials
to be relevant to clinical care in the
community. This tension has been de-
scribed as a distinction between pragmatic
and explanatory trials [4], between ex-
planatory and management trials [5], or
between mechanistic and practical trials
[6]. It may be difficult to interpret data
from trials that incorporate the most
relevant, and often highly variable, clinical
practices; for example, when fundamen-
tally different treatments are combined in
a single arm, bias or confounding may
exist within an arm. Conversely, a more
tightly controlled experiment may not
yield information that is widely applicable
or considered relevant.
Second, lack of consensus on the
current evidence base confounds attempts
to design new trials. Trials should build
upon previous evidence and address gaps
in knowledge, but achieving this goal
depends upon some agreement among
stakeholders about interpretation of the
state of current evidence and priorities for
research.
Disputes about Interpretations
of Evidence
Experts may disagree about interpreta-
tion of the available evidence and about
whether current treatments have been
validated by research (Box 1). This lack
of consensus on which treatments should
be considered ‘‘standard’’ can lead to
divergent views on the selection of a
comparison group, and more fundamen-
tally, dispute about what research question
is most relevant [7,8].
Designs that directly address the source
of the evidentiary controversy are valu-
able, but it might be impossible to design a
study that is acceptable to all. Experts may
disagree about whether there is sufficient
uncertainty to conduct a trial, or about the
risk–benefit profile of any particular de-
sign. Some might believe that evidence
already exists that a particular intervention
is inferior or poses serious risks; others who
believe that evidence is not clear might
advocate for a trial to compare competing
interventions.
In these situations, the most important
first step is to correctly identify the source
of disagreement about evidence, which
can then be a focus of discussion.
Lack of Adherence to Evidence-
Based Recommendations or
Practice Guidelines and Other
Variations in Medical Practice
Proven interventions may not be widely
used [9] because of low physician confi-
dence or knowledge, difficulty in imple-
mentation, cost, side effects, or patient
heterogeneity.
The choice of research question and
study design may depend on an analysis of
the factors driving the low utilization.
Disagreements can arise about whether a
validated treatment that is not used in the
community should be considered standard
and provided to a control group in a trial
(Box 2). If usual medical practice is used as
Box 1. Case Example: Taxanes and Ovarian Cancer Treatment
Before taxanes were available, first-line treatment for advanced ovarian cancer
consisted of carboplatin, either alone or in combination with other drugs. In the
early 1990s, four large trials were undertaken to determine if the addition of
taxanes could improve survival in patients with advanced disease [37–40]. Two
trials showed a survival benefit for patients on paclitaxel-containing regimens,
while two trials revealed no significant differences. One commentator [41]
outlined different explanations for the divergent trial results, such as differences
in the extent of treatment crossover among trials, differences in patients, and
differences in control arms. Experts in the US considered the positive trials to be
definitive, while those in the UK believed the trials showing equivalence carried
more weight.
Consequently, in an international collaboration involving the US, UK, and Canada,
national differences in practice guidelines—based on divergent views of the
evidence—led to disagreements about the appropriate reference arm in a trial
adding newer drugs to existing regimens. In the trial, Gynecologic Oncology
Group 182-International Collaborative Ovarian Neoplasm (ICON) 5 [42], the UK
investigators advocated for flexibility in the comparison group, due to their view
that taxane-containing regimens were equivalent to older regimens, but the US
investigators believed that paclitaxel must be included in first-line treatment. In
the end, the reference arm in the trial consisted solely of the paclitaxel-containing
regimen, and flexibility was not allowed [43].
Box 2. Case Example: The Enhanced Suppression of the Platelet
IIb/IIIa Receptor with Integrilin Trial (ESPRIT) Trial
ESPRIT was designed to determine the efficacy of a platelet glycoprotein (GP)
receptor antagonist, eptifibatide (Integrilin) in reducing the incidence of various
coronary events in percutaneous coronary intervention (PCI). During study
planning there was a vigorous debate about whether the trial should be have a
placebo or active control, namely abciximab [9,44]. In spite of evidence from
previous studies indicating positive effects of abciximab in PCI, this agent was not
used in 65%–75% of PCI procedures. Reasons for low usage were clinician
concerns about cost, safety, and efficacy; some physicians had doubts about the
applicability of previous trial data to current uses.
The FDA challenged the placebo-controlled study design [45]. A survey of
investigators at 49 ESPRIT sites revealed that only 30% used platelet GP IIb/IIA
inhibitors in management of PCI patients, and a substantial proportion of these
used the drugs in bail-out treatment. With these data the FDA and investigators
felt it was ethical to utilize a placebo control arm because it would not be
withholding from research participants a treatment they would otherwise receive,
although both the FDA and the investigators thought ‘‘usual care’’ was potentially
inferior to best practices.
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to less than optimal medical care; some
might defend such a design on the basis of
common practice in the community and
societal benefit from knowledge to be
gained. The acceptability of this approach
depends in part on whether there is a
possibility of serious or irreversible harm
to patients receiving usual care.
Where the prevailing practice is no
treatment, investigators might consider a
placebo control, but may be constrained
by ethical demands for an active compar-
ison group. There are existing guidelines
for the use of placebos [10,11] that define
specific criteria for their use.
If researchers test a new intervention
that could match the effectiveness of the
gold standard but is cheaper, easier, or
more accessible, it would be reasonable to
use the best known method as a compar-
ator in a noninferiority design. However, if
the new method is likely to be inferior to
the best known treatment but better than
the usual care patients actually receive, a
quandary remains: which existing method
should be used as a comparator?
Generally, noninferiority trials require
greater numbers of subjects than do
superiority trials, If a new intervention is
compared to best methods, the feasibility
of conducting the noninferiority trial
might be a limiting factor in getting the
research off the ground. A superiority trial
using an inferior reference arm might be
more feasible but objectionable because of
the less than optimal comparison group.
There is no consensus on how these
situations should be handled.
A trial might be designed as a strategy
trial to test an intervention delivered
according to a specific algorithm head-to-
head against the same intervention as used
in the community. The acceptability of
this design might depend on whether the
best-practices algorithm is widely consid-
ered more effective, or whether this is still
an open question.
An example of such a trial is the
Hypertension Detection and Follow-up
Program [12], which compared the effect
of Stepped Care versus community med-
ical therapy, with the primary endpoint
being five-year all-cause mortality. This
landmark study found that an intensive
management algorithm for hypertension
treatment improved outcomes, compared
to community care. It is interesting to note
that certain secondary outcomes could not
be assessed without bias, because of the
nature of the comparison arms. For
example, events diagnosed by direct ob-
servation, such as nonfatal myocardial
infraction, were not bias-free endpoints
due to the closer monitoring of the
Stepped Care arm compared to commu-
nity care. Therefore, all-cause mortality
was the sole primary endpoint. It is also
notable that research center staff took
direct steps to ensure that patients in the
community care arm with higher levels of
hypertension or major organ system ab-
normalities were seen by a community
provider.
There Is No Single ‘‘Best’’
Treatment: Different
Treatments Have Trade-offs in
Terms of Different Outcomes or
Side Effects
Two or more treatments for a single
condition may be characterized by differ-
ent profiles of performance across different
measures or side effects. Regimens can be
chosen on the basis not only of effective-
ness but also side effects or quality of life
[13,14]. Treatment choices may be made
on the basis of disease or patient charac-
teristics, on physician or patient prefer-
ences, or all of these factors (Box 3).
When available treatments present
trade-offs, patient preferences are often
particularly relevant [15–18]. A classically
randomized trial may be hindered by a
high refusal rate at recruitment or by
significant unplanned crossover between
or among arms after randomization. Some
investigators have explored partially ran-
domized designs that include randomized
groups and an observational arm in which
patients choose treatments [19] (Box 4).
Another option is testing a single treatment
versus a usual care arm allowing patient
and provider choice. This may increase the
relevance of the trial and enhance partic-
ipation. However, as in other not com-
pletely randomized studies, inferences that
can be made from a heterogeneous patient
preference arm are limited by possible
biases and confounding.
Box 3. Case Example: The Multi-modal Treatment Study of
ADHD (MTA)
The MTA [46–48] exhibited some features of the ‘‘gold standard’’ versus
community care approach. The main research question was about the relative
efficacy of drug treatment, behavioral treatment, or a combination of the two.
Therefore, the medication management, behavioral, and combination interven-
tions were carefully structured according to best practices to give what
investigators hoped would be the optimal results for each modality. Medication
management involved careful adjustment of dosage and choice of medication,
medication three times daily, and monthly follow-up visits and support. Intensive
behavioral treatment consisted of eight individual meetings interspersed with 27
group meetings to teach parents behavioral management techniques, an
intensive 8 week summer program for children, and classroom behavioral aides
during the fall of the school year. The third arm combined the medication and
behavioral interventions. A fourth arm consisted simply of referral to care in the
community, with follow-up and data collection in parallel with the other three
assigned treatment arms. Hence, the study included features of both explanatory
and pragmatic trials.
While the main research question in MTA was not about the adequacy of usual
care, the inclusion of the community care arm allowed some important data to be
collected about the effectiveness of usual care practices compared to the
intensive, carefully monitored interventions delivered in the other three trial arms.
Detailed data collection on procedures in the usual care arm informed further
work on translating the clinical trial results back into community practice [49].
Box 4. Case Example: The Spine Patient Outcomes Research Trial
(SPORT)
SPORT randomized patients to surgical versus nonsurgical treatments for back
pain [19]. Patients in the nonsurgical treatment arm were free to choose among a
long list of treatment alternatives. One of the strengths of this trial design is that
the wide range of practices used in the community were systematically
documented in the trial, rather than used covertly in a trial where only a subset
of available treatments are permitted and where patients may seek additional
care outside the trial itself.
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Evidence Base for Existing
Treatments
Often, treatments used in clinical prac-
tice have been insufficiently evaluated in
rigorous clinical trials. This problem may
occur with non-drug interventions or with
drugs that have not been tested against
relevant comparators. Clinical trial data
may be scanty, of poor quality, or based
on irrelevant patient populations; many
treatments have not been systematically
evaluated in randomized clinical trials
(RCTs) [20–22]. With this lack of evidence
it may not be clear which treatment is
preferable, or even if a given treatment is
better or worse than nothing.
Trials addressing these kinds of evidence
gaps could be designed with multiple arms
comparing existing interventions or compar-
ing a single intervention to a heterogeneous
group of treatments in the ‘‘usual care’’ arm.
The principal problem with this flexible
usual care group design is the limitations
on inferences that may be drawn unless
the single intervention is clearly superior.
In noninferiority trials, inferences could be
problematic if there is a lack of solid
evidence supporting effectiveness of a
usual care arm [23]. Also, heterogeneity
in the usual care group may make it
difficult to interpret and apply the results.
Physician Attitudes Regarding
Customized Patient Care
Selection of customized treatment based
on physician assessment of individual
patient characteristics [24] can lead to
scientific and practical challenges in mea-
suring effectiveness in clinical trials [25].
When many patient characteristics are
relevant, it would require impossibly large
trials to encompass all the stratified patient
subgroups needed to individually test all
the factors used in decision-making. In
such situations, physicians may object to
protocolized usual care treatment groups
in clinical trials, based on a belief that
physician discretion in treatment choices
provides superior outcomes [26–33]. In
addition, data, especially from explanatory
trials, come from carefully selected popu-
lations that differ in major ways from
patients treated in the community.
Physician decision-making can be tested
in a flexible usual care arm, although if
physicians vary in their criteria for assign-
ing individual treatments, it will be impos-
sible to make inferences about which set of
criteria is best. A preferable alternative is to
test disease management algorithms versus
usual practices [34,35].
Discussion
The choice of comparison arms in
clinical trials can be challenging when
there is no clear-cut uniform standard of
care. A variety of non-mutually exclusive
factors can feed the lack of consensus:
differing interpretations of existing evi-
dence, inadequate evidence, different bal-
ancing of trade-offs, a failure or inability to
implement evidence-based therapies, or a
belief in customized care.
It is critical to think systematically about
the background conditions in the practic-
ing medical community and goals of the
trial when grappling with the complexities
of heterogeneous medical practices. Mul-
tiple research questions could be impor-
tant, each requiring a different trial design.
At a minimum, the background conditions
of medical practices and beliefs should be
thoroughly explored, sometimes with qual-
itative as well as quantitative research.
Potential trial designs should be exam-
ined based on the following criteria:
N Scientific validity and strength of
inferences possible from a given de-
sign;
N Risks and benefits to participants in
chosen design versus alternative de-
signs;
N Relevance of the trial to current
practice, including relevance to pro-
vider and patient beliefs and values;
N Feasibility of the trial.
If a usual care arm is proposed, the
scientific rationale for including such an
arm should be carefully evaluated. It is
critical to consider whether the usual care
arm will contribute to meaningful infer-
ences about the relative merits of different
interventions in the trial, and whether the
protocol should restrict or intervene in
usual care. Design choices regarding
protocolized versus unrestricted usual care
often involve navigating a tension between
the need for rigor and clarity of evidence
versus practicality and relevance to clinical
practice.
If less than best accepted medical care is
provided in a trial arm it must be carefully
evaluated and justified. When there are
disputes about the adequacy of, or evi-
dence base for, any of the interventions
proposed for the trial, there may be no
consensus on whether trial participants are
adequately protected—these disagree-
ments about evidence should be frankly
acknowledged.
The relevance of the trial to current
practice should be described. Finally,
practical limitations should be acknowl-
edged, including infrastructure, costs, will-
ingness to participate, time constraints, or
other factors.
Not all ‘‘usual care’’ trials have similar
purposes. The SPORT trial (Box 4)
defines one end of the spectrum: a usual-
care arm that consists of a heterogeneous
mix of practices that are not mechanisti-
cally related. The result from such a trial
might be questioned as uninterpretable
because the comparator to the surgery
intervention is not defined. However, this
trial is a useful exploration, providing
evidence on a potpourri of treatments that
could help refine the comparisons made in
a future trial. Viewed from this perspec-
tive, the trial is akin to a high-quality
observational study, with randomization
reducing, but not eliminating, the con-
founding introduced by patient or physi-
cian choice. The trial then is helpful as
part of a series of studies in which no single
study is definitive. In fact, recently pub-
lished results [36] reveal that due to
extensive crossover between treatment
arms, it is impossible to draw clear
conclusions about relative effectiveness of
surgery versus nonsurgical treatments
from the trial results.
On the other end of the spectrum is the
ovarian cancer trial, in which a dispute
about the appropriate comparator was
resolved with a choice of one treatment
that was not yet universally used, but was
viewed by some as best proven therapy.
Such trials pose no problems of interpret-
ability. Trials that occupy an intermediate
category are those that use multiple arms
that implement different therapeutic ap-
proaches used in practice, but that share a
common mechanism, such as different
degree of the same therapy. In such trials,
the pattern of results among the arms
becomes relevant, as either a flat or
monotonic dose–response is expected.
The arms therefore ‘‘borrow strength’’
from each other in ways that mechanisti-
cally heterogeneous treatment choices or
combinations cannot.
Choices of control or comparator con-
ditions can become surrogates for debates
about the adequacy of current medical
practice, about current scientific evidence,
or about assessment of trade-offs among
treatment options. These debates can
affect judgments about whether sufficient
uncertainty exists to conduct the trial at
all; whether risks to subjects are mini-
mized; and whether the trial data will be
interpretable. Disputes about background
conditions complicate these already diffi-
cult discussions, and new empirical data
on practice patterns can help clarify such
debates. What is critical in all of these
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ment about usual care be recognized and
addressed separately from the question of
the trial design.
The goal should be that each trial will
contribute to the accumulation of knowl-
edge via a sequence of investigations,
which together lead to a causally coherent
understanding of treatment effects. Ulti-
mately, we want to answer why a treat-
ment is effective, by how much versus a
defined comparator, at what risk, and in
which patients. So an investigator must be
able to look beyond the trial in question
and explain how its results will inform
future research that lead to such an
understanding. Studies implementing
‘‘usual care’’ arms can complicate this
task, but if done right can ultimately lead
to results of great scientific relevance and
practical value.
Supporting Information
Text S1 Considering usual medical care
in clinical trial design: Scientific and
Ethical Issues Meeting, November 2005,
Bethesda, Maryland. In November 2005,
NIH and a number of other federal
agencies sponsored a meeting to discuss
clinical trial design challenges involving
selection of usual care comparison groups.
The planning committee for the meeting
consisted of the following individuals:
Duane Alexander, NIH/NICHD; Jona-
than Berman, NIH/NCCAM; Carolyn
Clancy, AHRQ; Ezekiel Emanuel, NIH/
Clinical Center; Ellen Feigal, NIH/NCI;
Lawrence Friedman, NIH/NHLBI; John
Gallin, NIH/Clinical Center; Saul Mal-
ozowski, NIH/NIDDK; Peter Mannon,
NIH/NIAID; Joan McGowan, NIH/
NIAMS; Amy Patterson, NIH/OD; Mar-
cel Salive, CMS; Bernard Schwetz,
OHRP; Belinda Seto, NIH/OER; David
Shore, NIH/NIMH; Lana Skirboll, NIH/
OD; Robert J. Temple, FDA; Deborah
Zarin, AHRQ. The meeting was informed
by a background paper outlining types of
challenges involved in selecting usual care
arms, prepared by a working group with
expertise in clinical trial design, ethics,
evidence-based medicine, statistics, and
science policy. The drafting group for the
background paper consisted of Liza Daw-
son,EzekielEmanuel,LawrenceFriedman,
Steven Goodman, and Deborah Zarin. At
the meeting, case study presentations were
made by Taylor Thompson, Mass. General
Hospital, Acute Respiratory Distress Syn-
drome Network (ARDSnet); Ann Marie
Swart, UK Medical Research Council,
International Collaborative Ovarian Neo-
plasm (ICON) Trials; James Swanson, UC
Irvine, Multimodal Treatment Study of
ADHD (MTA); James Weinstein, Dart-
mouth Medical School, Spine Patient
Outcomes Research Trial (SPORT). A full
presentation of each case study and panel
discussion is included in the meeting
proceedings document at http://crpac.od.
nih.gov/Draft_UsualCareProc_06062006_
cvr.pdf.
Found at: doi:10.1371/journal.pmed.
1000111.s001 (0.03 MB DOC)
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